Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS

Methods in Molecular Biology

Volumn 1045, Issue , 2013, Pages 285-293

  Basa, Louisette ^a  

^a GENENTECH INC   (United States)

Author keywords

Drug load distribution; Drug to antibody ratio (DAR); Electrospray ionization mass spectrometry (ESI MS); Integration of mass spectra

Indexed keywords

ARTICLE; CALCULATION; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG DISTRIBUTION; DRUG TO ANTIBODY RATIO; ELECTROSPRAY MASS SPECTROMETRY; PARAMETERS; PRIORITY JOURNAL;

EID: 84934439376     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_18     Document Type: Article

References (23)

1. Laguzza BC, Nichols CL et al (1989) New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation and representative in vivo activity. J Med Chem 32:548-555
2. Greenfield RS, Kaneko T et al (1990) Evaluation in vitro of Adriamycin immunoconjugates synthesized using an acid-sensitive hydrazine linker. Cancer Res 50:6600-6607
3. Hudecz F, Garnett MC et al (1992) The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography. Biomed Chromatogr 6:128-132
4. Chari RV, Martell BA et al (1992) Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131
5. Willner D, Trail PA et al (1993) (6-Maleimidocaproyl) hydrazine of doxorubicin -new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 4:521-527
6. Hinman LM, Hamann PR et al (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins; a novel and potent family of antitumor antibiotics. Cancer Res 53:3336-3342
7. Chari RV, Jackel KA et al (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55:44079-44084
8. Moran J (2002) Presentation at the 224th American Chemical Society National Meeting, Boston, MA; 18-22 August 2002
9. Hamblett KJ, Senter PD et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070
10. Wakankar A, Chen Y et al (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3 (2):161-172
11. McDonagh CF, Turcott E et al (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19:299-307
12. Wang L, Amphlett G et al (2005) Structural characterization of the maytansinoidmonoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:436-446
13. Lazar AC, Wang L et al (2005) Analysis of the composition of immunoconjugates using sizeexclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 19:1806-1814
14. Junutula JR, Flagella KM et al (2010) Engineered thiotrastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769-4778
15. Xu K, Liu L et al (2011) Characterization of intact antibody-drug conjugates from plasma/ serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 412:56-66
16. Siegel MM, Hollander IJ et al (1991) Matrixassisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator and conjugated drug content. Anal Chem 63:2470-2481
17. Quiles S, Raisch KP et al (2010) Synthesis and preliminary biological evaluation of high-drugload paclitaxel-Antibody conjugates for tumortargeted chemotherapy. J Med Chem 53:586-594
18. Safavy A, Bonner JA et al (2003) Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bionconjug Chem 14:302-310
19. Valliere-Douglass JF, McFee WA, Salas-Solano O (2012) Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal Chem 84:2843-2849
20. Jiang X, Song A et al (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101-111
21. Harris RJ (1995) Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 705:129-134
22. Sun MM, Beam KS et al (2005) Reductionalkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282-1290
23. Duchateau ALL, Munsters BHM et al (1991) Selection of buffers and of an ion-pairing agent for thermospray liquid chromatographic-mass spectrometric analysis of ionic compounds. J Chromatogr A 552:605-612